Professor Jonathan Williams, one of the UK’s leading organic chemists, has received a Royal Society Wolfson Merit Award for his research.
Williams, from the University of Bath’s Department of Chemistry, is the recipient of a £10,000 a year award over a five-year period. The award will fund his research group’s work in designing metal catalysts for new chemical reactions.
In many cases, the metal catalysts developed by the group allow reactions to be more environmentally friendly because molecules can be constructed more efficiently and use less energy.
Professor Paul Raithby, Head of the Department of Chemistry, said: ‘Jonathan is undoubtedly one of the most creative and productive organic chemists of his generation in the UK. His work has influenced academic chemistry internationally, as well as having had significant impact in industrial practice.
‘Jonathan has attracted a talented group of organic chemists to Bath and we are determined to support him in further developing the department’s international reputation as a leading centre for catalysis and chemical synthesis. This award is a significant contribution to that goal.’
Until recently, the research group worked on a method of constructing chemical bonds using catalytic reactions that they termed ‘Borrowing Hydrogen Methodology’. This focused on the metal catalyst temporarily removing hydrogen from the starting material, allowing it to react more easily.
Williams said: ‘The resulting compounds from this technique are made more cleanly than they would be traditionally. Using our methodology, the only by-product created is water, and there is no need to use carcinogenic starting materials.’
The group has since changed its focus and the Wolfson Merit Award will fund research into new catalytic reactions.
‘We’re now focusing on developing new approaches to the formation of amides, the chemical bonds found in proteins, in many drug molecules, and in robust materials such as Nylon and Kevlar,’ said Williams.
‘This new research will aim to identify catalytic methods for the formation of amides, which are traditionally prepared using cumbersome, inefficient chemistry.’
Bath professor receives Wolfson Merit Award
The award will fund Jonathan Williams\' research into metal catalysts for new chemical reactions
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development
Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies
Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development
Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation
New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines
Manufacturing
Bruker announces major strides in 4D proteomics performance, further advances In intact and top-down functional proteoform analysis, and innovations in hybrid qual/quant 4D metabolomics
All to enable deeper insights into disease biology. Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry Research, and in Semiconductor Manufacturing